



**CanVeer**  
**Biopharma**

*Innovative science to safeguard every  
newborn's first breath*

# Corporate Presentation

June 2026

# Forward Looking Statement



This document and any attachments are intended for information purposes only and should not be construed as an offer or solicitation for the sale of securities. Statements in this presentation include forward-looking statements within the meaning of certain securities laws. These forward-looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words “expected to” “illustrate” “has the potential to” “will be”, “evaluating” “plans” “can be” “planning” “to predict” “potential” “may” “should” and words and expressions of similar import, are intended to identify forward-looking statements. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not put undue reliance on these statements or the scientific data presented as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. We do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.

# The Medical Need: Bronchopulmonary Dysplasia (BPD)




## “A Preterm Newborns Crisis”


BPD is a severe respiratory condition that affects ~40% of preterm newborns who require oxygen support at birth for survival

~35,000 newborn babies lose their life every year in North America due to BPD

- ❑ **Prognosis & Severity:** >25% morbidity. If survived, suffer hypertension, chronic Asthma, frequent lung infections & others
- ❑ **Epidemiology:** In North America, annually ~140,000 newborns are at risk of BPD
- ❑ **Standard of Care:** No approved disease modifying therapy
- ❑ **Healthcare Burden:** \$600K+ in year one for each newborn who develops BPD



# The Solution: AlveoShield, a Disease Modifying Therapeutic Candidate for BPD



- ❑ **Lungs epithelial cell death is a primary driver leading to BPD development.**
- ❑ Oxygen therapy-induced lung injury triggers epithelial cell death, which directly inhibits normal lung development, leading to the development of the BPD condition.
- ❑ **AlveoShield treatment targets & blocks epithelial cell death pathway, restoring normal development of lungs (alveolarization) while receiving oxygen support**

## Reference:



**Yeganeh B, Lee J, Bilodeau C, Lok I, Ermini L, Ackerley C, Caniggia I, Tibboel J, Kroon A, Post M. Acid Sphingomyelinase Inhibition Attenuates Cell Death in Mechanically Ventilated Newborn Rat Lung. *Am J Respir Crit Care Med.* 2019 Mar 15;199(6):760-772.**

# Scientific Evidence & Preclinical Efficacy






## Human Tissue Validation

AlveoShield's "targets" are highly expressed in BPD-affected newborns' lung tissue






## Characterized Biological Pathway & Biomarkers

AlveoShield blocks BPD pathway in human lung cell lines



## Safety, dose & preclinical utility in BPD rat pups' model

Lung development restored with AlveoShield treatment



# Milestones Achieved to Date - A *De-risked Opportunity*



## Characterized Biological Mechanism & Biomarkers

(*in vitro* lung cell lines)

## Human Tissue Validation

Target validated in newborn lung tissue  
(47 patients - postmortem neonates)

## Pre-Clinical *in vivo* Efficacy

Safety/ Dose response/ clinical utility  
(Juvenile neonate rat pups)

## IP Secured: Provisional Patent Filed & IP Assignments Completed

(IP rights solely owned by CanVeer)

## Accepted into IPON Program

Ontario non-dilutive funding  
(300k lifetime at 80% contribution)

## International Patent Filed (PCT)

National & International IP rights  
locked for 20 years





- ❑ **Eligible for: 505(b)(2)** accelerated regulatory approval
- ❑ **Eligible for:** Orphan Disease Drug Designation (**ODD**), Rare Pediatric Disease Designation (**RPD**), & potentially, Breakthrough Therapy Designation
- ❑ **Clinical utility: First-in-Class** disease modifying therapeutic, that prevents lung damage from the root cause
- ❑ **Use Case:** Intended for use in **all** preterm newborns receiving oxygen support (**invasive or non-invasive**)



# Market Potential & Go-to-Market Plan



- ✓ **Market Size:** ~140,000 eligible infants annually in Canada & the USA
- ✓ **Projected Pricing:** Market standard for Rare Pediatric Disease -*(Conservative median)* \$100,000 per course (*DrugPatentWatch 2025 & Reuters Report 2025*)
- ✓ **TAM:** \$14B+ in NA (~\$6B peak sales @ 40% market penetration)
- ✓ **Distribution:** NICU-focused through hospital internal pharmacies
- ✓ **Business Model:** High potential for early exit with neonatal focused big pharma (Chiesi, Mallinckrodt, Abbott & Roche)



<https://www.reuters.com/business/healthcare-pharmaceuticals/prices-new-us-drugs-doubled-4-years-focus-rare-disease-grows-2025-05-22/>

# Recent Comparable Exits - M&As



Comparator	Exit/ Value	Relevance
<b>Synnovation Therapeutics</b>	Acquisition @ <b>3B</b> (Novartis) - 2026	<b>Phase1/2</b> - small molecule
<b>35Pharma Inc.</b>	Acquisition @ <b>950M</b> (GSK) - 2026	<b>Phase1</b> - Canadian startup - respiratory
<b>Kate Tx</b>	Acquisition @ <b>1.1B</b> (Novartis) - 2025	<b>Preclinical stage</b> - special organ delivery
<b>Day-One-Bio</b>	Acquisition @ <b>2.5B</b> (Servier) - 2026	<b>Pediatric</b> - late stage
<b>Orphelia</b>	Acquisition - <b>Private</b> (Orphalan) - 2026	<b>Orphan pediatric</b> - clinical trial stage
<b>TheraB Medical</b>	Acquisition - <b>Private</b> (Natus) - 2025	<b>Neonatal care</b>
<b>Airway Therapeutics</b>	<b>Series A</b> USD\$18M at Phase 1B	<b>BPD-space</b>

# Dedicated - Seasoned, Co-Founders, Leadership & Worldclass Advisory Board



**Sherif Louis, PhD, MBA  
CEO**



**Dr. Behzad Yeganeh, PhD  
CSO & Inventor**

- ✓ **15+ years biotech Executive leadership**
- ✓ **Successfully commercialized academic healthcare IP**
- ✓ **Multiple rounds of multimillion dollars capital raises**
- ✓ **Deep regulatory experience (ISO, CAP, CLIA certifications)**

- ✓ **20+ years of cutting-edge health research**
- ✓ **Leading neonatal lung injury researcher**
- ✓ **60+ publications in high-impact journals**
- ✓ **Strong KOL network in neonatology**
- ✓ **Inventor on several patents**

## Clinical Advisory Board

**Dr. Martin Post  
(Co-Inventor)**



**Dr. Robert Jankov  
(Co-Inventor)**




**Dr. Estelle Gauda**



**Dr. Michael Dunn**



## Expert Management Team



**Ali Hamraghani, PharmD, MSc  
VP, Product Development**



**Azadeh Yeganeh, PhD  
VP, Regulatory Affairs**



## SIGNIFICANT MARKET

- In North America, every year ~**140,000** preterm newborns require oxygen support to survive and are at risk to develop BPD, leading to **TAM of ~\$14B; ~\$6B peak sales @ 40% market penetration**

## PRECLINICAL EFFICACY

- **First-in-Class disease-modifying approach.** AlveoShield, is designed to target and block the biological drivers of lung injuries.
- AlveoShield is supported by preclinical human tissue & animal model validation

## ACCELERATED APPROVAL

- **Eligible for 505(b)(2)** accelerated regulatory approval based on existing safety data
- **AlveoShield™ is eligible for: ORPHAN DRUG; RARE PEDIATRIC DISEASE; BREAKTHROUGH THERAPY**

## SECURED IP & EXPERIENCED LEADERSHIP

- PCT Patent filed in May 2026; Provisional Patent filed in 2025. **IP protected till 2045.** IP rights are owned by CanVeer Biopharma Inc. (**no royalty provisions**)
- The Leadership Team brings **>40 years** of combined experience leading Healthcare Innovation & Commercialization



**CanVeer**  
Biopharma

*Innovative science to safeguard every newborn's first breath.*

**Contact:**

Sherif Louis  
CEO

E: [info@canveer.com](mailto:info@canveer.com)

T: 647-293-6555

w: [www.canveer.com](http://www.canveer.com)